138
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Analysis of Treponema pallidum DNA and CXCL13 in Cerebrospinal Fluid in HIV-Negative Syphilis Patients

ORCID Icon, , , & ORCID Icon
Pages 7791-7798 | Received 23 Oct 2022, Accepted 16 Dec 2022, Published online: 29 Dec 2022

References

  • Gonzalez H, Koralnik IJ, Marra CM. Neurosyphilis. Semin Neurol. 2019;39(4):448–455. doi:10.1055/s-0039-1688942
  • Tong ML, Zhao Q, Liu LL, et al. Whole genome sequence of the Treponema pallidum subsp. pallidum strain Amoy: an Asian isolate highly similar to SS14. PLoS One. 2017;12(8):e0182768. doi:10.1371/journal.pone.0182768
  • Yu Q, Cheng Y, Wang Y, et al. Aberrant humoral immune responses in neurosyphilis: CXCL13/CXCR5 play a pivotal role for B-cell recruitment to the cerebrospinal fluid. J Infect Dis. 2017;216(5):534–544. doi:10.1093/infdis/jix233
  • Pilz G, Sakic I, Wipfler P, et al. Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction. Fluids Barriers CNS. 2020;17(1):7. doi:10.1186/s12987-020-0170-5
  • Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1
  • Marra CM. Neurosyphilis. Continuum. 2015;21(6Neuroinfectious Disease):1714–1728. doi:10.1212/CON.0000000000000250
  • Zhu L, Gu X, Peng RR, et al. Comparison of the cerebrospinal fluid (CSF) toluidine red unheated serum test and the CSF rapid plasma reagin test with the CSF venereal disease research laboratory test for diagnosis of neurosyphilis among HIV-negative syphilis patients in China. J Clin Microbiol. 2014;52(3):736–740. doi:10.1128/JCM.02522-13
  • Lu Y, Ke W, Yang L, et al. Clinical prediction and diagnosis of neurosyphilis in HIV-negative patients: a case-control study. BMC Infect Dis. 2019;19(1):1017. doi:10.1186/s12879-019-4582-2
  • Ge Y, Gou X, Dong X, Peng Y, Yang F. Cerebrospinal fluid changes and clinical features of neurosyphilis compared with latent syphilis infection in the central nervous system: a cross-sectional study. Infect Drug Resist. 2022;15:5377–5385. doi:10.2147/IDR.S371446
  • Ropper AH, Longo DL. Neurosyphilis [published correction appears in N Engl J Med. 2019 Oct 31;381(18):1789]. N Engl J Med. 2019;381(14):1358–1363. doi:10.1056/NEJMra1906228
  • Hook EW 3rd. Syphilis [published correction appears in Lancet. 2019 Mar 9;393(10175):986]. Lancet. 2017;389(10078):1550–1557. doi:10.1016/S0140-6736(16)32411-4
  • Palmer HM, Higgins SP, Herring AJ, Kingston MA. Use of PCR in the diagnosis of early syphilis in the United Kingdom. Sex Transm Infect. 2003;79(6):479–483. doi:10.1136/sti.79.6.479
  • Hagihara M, Yamagishi Y, Kato H, et al. Frequency of Treponema pallidum invasion into cerebrospinal fluid in primary or secondary early-stage syphilis. J Infect Chemother. 2018;24(5):404–406. doi:10.1016/j.jiac.2017.11.007
  • Vanhaecke C, Grange P, Benhaddou N, et al. Clinical and biological characteristics of 40 patients with neurosyphilis and evaluation of Treponema pallidum nested polymerase chain reaction in cerebrospinal fluid samples. Clin Infect Dis. 2016;63(9):1180–1186. doi:10.1093/cid/ciw499
  • Salle R, Grange PA, Ollagnier G, Benhaddou N, Heller U, Dupin N. Comparison of molecular and serological assays on cerebrospinal fluid for the diagnosis of neurosyphilis [published online ahead of print, 2022 Sep 27]. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18604
  • Gao ZX, Gou Y, Liu XQ, Peng LW. Advances in laboratory diagnostic methods for cerebrospinal fluid testing for neurosyphilis. Front Public Health. 2022;10:1030480. doi:10.3389/fpubh.2022.1030480
  • Tuddenham S, Katz SS, Ghanem KG. Syphilis laboratory guidelines: performance characteristics of nontreponemal antibody tests. Clin Infect Dis. 2020;71(Suppl 1):S21–S42. doi:10.1093/cid/ciaa306
  • Marra CM, Maxwell CL, Dunaway SB, Sahi SK, Tantalo LC, Munson E. Cerebrospinal fluid Treponema pallidum particle agglutination assay for neurosyphilis diagnosis. J Clin Microbiol. 2017;55:1865–1870. doi:10.1128/JCM.00310-17
  • Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal-specific tests for the diagnosis of syphilis. Clin Infect Dis. 2020;71(Suppl 1):S13–S20. doi:10.1093/cid/ciaa349
  • Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis. 2010;37(5):283–287. doi:10.1097/OLQ.0b013e3181d877a1
  • Dersch R, Hottenrott T, Senel M, et al. The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids Barriers CNS. 2015;12:12. doi:10.1186/s12987-015-0008-8
  • Zeng YL, Lin YQ, Zhang NN, et al. CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients. Springerplus. 2016;5(1):743. doi:10.1186/s40064-016-2462-4
  • Mothapo KM, Verbeek MM, van der Velden LB, et al. Has CXCL13 an added value in diagnosis of neurosyphilis? J Clin Microbiol. 2015;53(5):1693–1696. doi:10.1128/JCM.02917-14
  • Yan Y, Wang J, Qu B, et al. CXCL13 and TH1/Th2 cytokines in the serum and cerebrospinal fluid of neurosyphilis patients. Medicine. 2017;96(47):e8850. doi:10.1097/MD.0000000000008850
  • Lepennetier G, Hracsko Z, Unger M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. J Neuroinflammation. 2019;16(1):219. doi:10.1186/s12974-019-1601-6
  • Li D, Huang X, Shi M, Luo L, Tao C. Diagnostic role of CXCL13 and CSF serology in patients with neurosyphilis. Sex Transm Infect. 2021;97(7):485–489. doi:10.1136/sextrans-2020-054778